IRMD FINANCIAL STATEMENTS

Iradimed Co — balance sheet, income statement and cash flow trends

IRMDIradimed Co

🇺🇸 USA · NASDAQ · Healthcare · Medical Devices

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue86.3 M $+14.8%

Gross Profit66.3 M $+14.7%

Operating Income28 M $+23.4%

EBITDA32.2 M $+25.1%

Net Income23.6 M $+19.3%

Peer Comparison· Medical Devices

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
IRMD	14.8%	76.8%	37.4%	27.4%
4DX	-26.0%	-396.6%	-818.8%	-3,684.6%
COH	2.0%	73.0%	24.0%	14.6%
SN	—	68.0%	25.6%	10.1%
ONCSM	39.1%	48.4%	30.6%	6.3%
MEDTR	6.5%	30.9%	9.4%	0.2%
Industry median	7.4%	58.9%	5.2%	-5.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
IRMD	14.8%	76.8%	37.4%	27.4%
ENOV	6.0%	56.8%	-32.8%	-49.9%
INSP	8.9%	85.8%	8.8%	14.3%
QDEL	-3.9%	45.0%	-20.7%	-45.6%
ATEC	22.5%	65.3%	-0.2%	-15.9%
IART	1.2%	53.2%	-17.6%	-30.1%
Industry median	7.4%	58.9%	5.2%	-5.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity98.5 M $86%
Current Liabilities12.1 M $11%
Long-term Liabilities3.8 M $3%

Key Figures

YoY change

Total Assets114.4 M $+12.4%

Total Liabilities15.9 M $+36.0%

Total Equity98.5 M $+9.4%

Cash & ST Investments56.4 M $+12.0%

Total Debt——

Net Debt-56.4 M $—

Peer Comparison· Medical Devices

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
IRMD	7.13	—	—	86.1%
4DX	6.57	-22.6%	0.71	-20.4%
COH	2.46	22.1%	0.42	69.4%
SN	2.57	62.9%	1.72	50.6%
ONCSM	2.25	35.0%	0.42	56.4%
MEDTR	3.58	1.0%	-1.64	83.0%
Industry median	3.28	44.7%	0.82	49.7%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
IRMD	7.13	—	—	86.1%
ENOV	2.04	95.5%	-1.84	38.5%
INSP	6.34	3.7%	-3.17	86.9%
QDEL	1.43	155.3%	-4.98	32.9%
ATEC	1.90	3,303.4%	-341.81	2.3%
IART	3.38	195.6%	-6.13	29.1%
Industry median	3.28	44.7%	0.82	49.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow28.9 M $+11.2%

Capital Expenditures4.8 M $-59.7%

Free Cash Flow24.1 M $+72.2%

Dividends Paid-15.4 M $-296.3%

Peer Comparison· Medical Devices

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
IRMD	33.5%	27.9%	5.6%	122.6%
4DX	-761.6%	-530.7%	3.7%	20.7%
COH	11.2%	8.5%	2.7%	76.6%
SN	20.8%	13.8%	7.0%	205.6%
ONCSM	6.2%	-5.5%	12.0%	99.3%
MEDTR	21.1%	27.9%	6.6%	10,700.8%
Industry median	7.2%	1.5%	4.1%	76.6%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
IRMD	33.5%	27.9%	5.6%	122.6%
ENOV	10.7%	1.6%	9.1%	-21.4%
INSP	14.9%	10.6%	4.4%	104.1%
QDEL	0.2%	-2.8%	4.0%	-0.5%
ATEC	6.6%	0.9%	5.7%	-41.1%
IART	4.3%	-0.6%	5.0%	-14.4%
Industry median	7.2%	1.5%	4.1%	76.6%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on IRMD

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 7, 26. This content is for informational purposes only and is not investment advice.